Multicenter Trial for Adults With Partial Seizures
Launched by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. · May 2, 2002
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • must weigh greater than or equal to 40kg
- • Patients must have diagnosis of partial seizures
- • At least 3 observable partial seizures a month
- • Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.
- Exclusion:
- • Patients on Valproic acid, and Felbamate
About Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc. is a leading global pharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong emphasis on delivering high-quality medicines across various therapeutic areas, Teva leverages its extensive expertise in drug development and manufacturing to advance healthcare outcomes. The company's commitment to scientific excellence and patient-centric approaches drives its clinical trial initiatives, focusing on addressing unmet medical needs and improving the quality of life for patients worldwide. Through robust partnerships and a comprehensive portfolio, Teva continues to play a pivotal role in the pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials